Trial site
Hope and Healing Cancer Services
Hinsdale, Illinois 60521, United StatesNot linked to an institution yet
- 15running trials
- 5closed trials
The trials here
What the 20 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 1/24 trials
- Phase 24 trials
- Phase 41 trial
- Status
- Recruiting9 trials
- Active, not recruiting5 trials
- Completed2 trials
- Terminated2 trials
- Not yet recruiting1 trial
- Withdrawn1 trial
- Lead sponsor
- Pfizer4 trials
- Janssen Research & Development, LLC2 trials
- Aadi Bioscience, Inc.1 trial
- Amgen1 trial
- Artios Pharma Ltd1 trial
- and 11 more
Running trials
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· Phase 3· Daiichi Sankyo· Source
Recruiting
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07043400· Phase 3· BeOne Medicines· Source
Contact: BeOne Medicines
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· Phase 3· Pfizer· Source
Recruiting
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
NCT06937177· Phase 2· Endevica Bio· Source
Contact: Srilata Gundala, MD
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834· Phase 3· Gilead Sciences· Source
Recruiting
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
NCT06562543· Phase 4· Takeda· Source
Contact: Srilata Gundala (principal investigator)
Active, not recruiting
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· Phase 3· Pfizer· Source
Recruiting
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT06246916· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Active, not recruiting
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT05963074· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623· Phase 3· Pfizer· Source
Recruiting
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
NCT05455619· Phase 1/2· SynDevRx, Inc.· Source
Contact: Srilata Gundala, MD (principal investigator)
Recruiting
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114· Tempus AI· Source
Contact: Ellen Gustafson
Recruiting
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068· Phase 1/2· Artios Pharma Ltd· Source
Contact: Sarah Cannon Development Innovations
Active, not recruiting
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599· Phase 1/2· Genmab· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error